GlassScriptPhysician profile
Scott L Gottlieb
NPI 1720185515
$35,624.34
in general payments reported to CMS, 2019-2025
29 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $26K · 2021: $2,080 · 2022: $3,551 · 2023: $997 · 2024: $891 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25,658.18 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $3,679.23 | 2019-2025 | Proclaim, Eterna |
| Scilex Pharmaceuticals INC. | $1,066.15 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $1,037.27 | 2019-2025 | Belbuca, Xtampza |
| Arbor Pharmaceuticals, INC. | $491.12 | 2019-2022 | |
| Nevro Corp. | $459.67 | 2019-2023 | Senza |
| Lilly USA, LLC | $373.15 | 2022 | |
| Medtronic, INC. | $366.35 | 2023-2024 | Intellis Adaptivestim |
| Almatica Pharma LLC | $326.28 | 2021-2023 | Gralise, Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.96 | 2019-2025 | Relistor |
| Assertio Therapeutics, INC. | $264.21 | 2019-2020 | |
| Saluda Medical Americas, INC. | $243.01 | 2023-2025 | Evoke, Evoke Scs |
| Redhill Biopharma INC. | $218.21 | 2021-2022 | |
| Horizon Therapeutics Plc | $178.36 | 2019-2021 | |
| Pfizer INC. | $136.08 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $126.23 | 2023-2025 | Horizant, Horizant |
| Depuy Synthes Sales INC. | $99.96 | 2019-2022 | |
| Si-Bone, INC. | $99.25 | 2019-2024 | |
| Nalu Medical, INC. | $78.11 | 2021 | |
| Greenwich Biosciences, INC. | $76.50 | 2019 | |
| Fidia Pharma USA INC. | $63.63 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $60.69 | 2022-2023 | Seglentis |
| Ibsa Pharma INC. | $53.56 | 2020-2021 | |
| Biotronik Nro, INC. | $44.73 | 2024 | Prospera |
| Astrazeneca Pharmaceuticals LP | $38.06 | 2019 | |
| Relievant Medsystems, INC. | $31.72 | 2023 | Intracept |
| Biodelivery Sciences International, INC. | $29.01 | 2020 | |
| Shionogi INC | $28.95 | 2019 | |
| Curonix LLC | $24.71 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gottlieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.